HUE030811T2 - Netupitant és palonosetron terápiás kombinációi - Google Patents
Netupitant és palonosetron terápiás kombinációi Download PDFInfo
- Publication number
- HUE030811T2 HUE030811T2 HUE12784677A HUE12784677A HUE030811T2 HU E030811 T2 HUE030811 T2 HU E030811T2 HU E12784677 A HUE12784677 A HU E12784677A HU E12784677 A HUE12784677 A HU E12784677A HU E030811 T2 HUE030811 T2 HU E030811T2
- Authority
- HU
- Hungary
- Prior art keywords
- pain
- netupitant
- dose
- use according
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548514P | 2011-10-18 | 2011-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE030811T2 true HUE030811T2 (hu) | 2017-05-29 |
Family
ID=47178220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12784677A HUE030811T2 (hu) | 2011-10-18 | 2012-10-10 | Netupitant és palonosetron terápiás kombinációi |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9358228B2 (https=) |
| EP (2) | EP2759298B1 (https=) |
| JP (1) | JP2014530249A (https=) |
| CN (3) | CN106974912A (https=) |
| DK (1) | DK2744497T3 (https=) |
| ES (1) | ES2579616T3 (https=) |
| HK (1) | HK1198121A1 (https=) |
| HU (1) | HUE030811T2 (https=) |
| PL (1) | PL2744497T3 (https=) |
| PT (1) | PT2744497T (https=) |
| WO (1) | WO2013057554A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3435980T (pt) * | 2016-06-06 | 2020-02-21 | Helsinn Healthcare Sa | Formulações injetáveis fisiologicamente equilibradas de fosnetupitant |
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| TW202428273A (zh) | 2023-01-03 | 2024-07-16 | 瑞士商赫爾辛保健公司 | 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL166272B1 (pl) | 1989-11-28 | 1995-04-28 | Syntex Inc | Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| ES2327600T3 (es) * | 1999-02-18 | 2009-11-02 | Novasearch Ag | Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas. |
| EP1394150B1 (en) | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| PT1303490E (pt) | 2000-07-14 | 2008-09-04 | Hoffmann La Roche | Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina |
| MXPA03005169A (es) | 2000-12-14 | 2003-09-22 | Hoffmann La Roche | Matriz lipidica auto-emulsificante. |
| MXPA05007381A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para el tratamiento de transtornos funcionales del intestino. |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
| JO2676B1 (en) * | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| JP2008505107A (ja) | 2004-07-01 | 2008-02-21 | シェーリング コーポレイション | Ｎｋ１アンタゴニストとしてのピペリジン誘導体 |
| WO2007128056A1 (en) * | 2006-05-03 | 2007-11-15 | Cnsbio Pty Ltd | Methods and composition for treatment of inflammatory pain |
| CN101573106B (zh) | 2006-10-24 | 2013-07-24 | 赫尔辛医疗股份公司 | 具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂 |
| US20100316678A1 (en) | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
| PT2722045T (pt) * | 2009-11-18 | 2016-10-18 | Helsinn Healthcare Sa | Composições para o tratamento de náuseas e vómitos mediadas centralmente |
-
2012
- 2012-10-10 ES ES12784677.2T patent/ES2579616T3/es active Active
- 2012-10-10 WO PCT/IB2012/002013 patent/WO2013057554A2/en not_active Ceased
- 2012-10-10 DK DK12784677.2T patent/DK2744497T3/en active
- 2012-10-10 US US14/351,113 patent/US9358228B2/en active Active
- 2012-10-10 JP JP2014536344A patent/JP2014530249A/ja active Pending
- 2012-10-10 CN CN201610834008.7A patent/CN106974912A/zh active Pending
- 2012-10-10 HU HUE12784677A patent/HUE030811T2/hu unknown
- 2012-10-10 CN CN201510670710.XA patent/CN105412110B/zh active Active
- 2012-10-10 PL PL12784677.2T patent/PL2744497T3/pl unknown
- 2012-10-10 EP EP14165604.1A patent/EP2759298B1/en active Active
- 2012-10-10 CN CN201280051509.8A patent/CN103889423B/zh active Active
- 2012-10-10 PT PT127846772T patent/PT2744497T/pt unknown
- 2012-10-10 EP EP12784677.2A patent/EP2744497B1/en active Active
-
2014
- 2014-08-14 HK HK14110976.1A patent/HK1198121A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1194977A1 (zh) | 2014-10-31 |
| WO2013057554A2 (en) | 2013-04-25 |
| US20140256737A1 (en) | 2014-09-11 |
| EP2759298A1 (en) | 2014-07-30 |
| JP2014530249A (ja) | 2014-11-17 |
| CN103889423B (zh) | 2016-10-19 |
| CN105412110B (zh) | 2018-05-25 |
| CN106974912A (zh) | 2017-07-25 |
| DK2744497T3 (en) | 2016-08-01 |
| WO2013057554A3 (en) | 2013-07-11 |
| US9358228B2 (en) | 2016-06-07 |
| EP2744497B1 (en) | 2016-04-06 |
| PT2744497T (pt) | 2016-07-18 |
| ES2579616T3 (es) | 2016-08-12 |
| EP2744497A2 (en) | 2014-06-25 |
| CN105412110A (zh) | 2016-03-23 |
| HK1198121A1 (en) | 2015-03-13 |
| PL2744497T3 (pl) | 2016-10-31 |
| CN103889423A (zh) | 2014-06-25 |
| EP2759298B1 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wong et al. | Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain | |
| Diamond et al. | Ginkgo biloba extract: mechanisms and clinical indications | |
| Rice et al. | Lactate administration attenuates cognitive deficits following traumatic brain injury | |
| ES2241651T3 (es) | Utilizacion de la nicotina o de sus derivados y de la l-dopa en un medicamento destinado al tratamiento de enfermedades neurologicas, especialmente la enfermedad de parkinson. | |
| KATZ et al. | The natural course of creeping eruption and treatment with thiabendazole | |
| US20100035978A1 (en) | Combination of cannabinoids for the treatment of peripheral neuropathic pain | |
| ES2709849T3 (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxia | |
| PT1128835E (pt) | Tratamento com cianocobalamina (vitamina b12) em doença alérgica | |
| HUE030811T2 (hu) | Netupitant és palonosetron terápiás kombinációi | |
| ES3004332T3 (en) | Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene | |
| EP0575613A4 (de) | Arzneimittel mit antistress-, stressschutz- und nootroper wirkung. | |
| Moreira et al. | Physical exercise protects myenteric neurons and reduces parasitemia in Trypanosoma cruzi infection | |
| ES2538088T5 (es) | Extractos vegetales de Sideritis y su uso para el aumento de la capacidad cognitiva | |
| Sharp et al. | Options for pharmacoresistant epilepsy in children: when medications don’t work | |
| ES2329815T3 (es) | S-mirtazapina para el tratamiento de sofocos. | |
| ES2952610T3 (es) | Métodos para tratar o aliviar trastornos mentales y síntomas asociados | |
| Patel et al. | Emergency Critical Care of Accidental High Fall in a Wild Indian Palm Squirrel (Funambulus palmarum) | |
| ES2356371T3 (es) | Medicamentos terapéuticos para inducir tolerancia. | |
| CN118593461B (zh) | 一种组合物、药物及其制备、检测、定位方法和用途 | |
| Mojarad et al. | Comparison of the antinociceptive effect of intrathecal versus intraperitoneal injection of paracetamol in neuropathic pain condition | |
| Allison | Total plasma ascorbic acid as index of stress in the rat | |
| Jayasri et al. | Research Article ISSN 2582-0109 | |
| Afif | Fighting Viruses And Promoting Mental Health By Gemstones And Myrrh Liquid With Aloe Vera | |
| CN108245510B (zh) | 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途 | |
| Kokare et al. | A REVIEW ON THERAPEUTIC USES OF VANGA BHASMA |